Camptothecin (NSC-100880, CPT, Campathecin, (S)-(+)-Camptothecin) is a specific inhibitor of DNA topoisomerase I (Topo I) with an IC50 of 0.68 μM. Camptothecin induces apoptosis in cancer cells through the microRNA- 125b-mediated mitochondrial signaling pathway to induce apoptosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
100 mg | In stock | $ 55 | |
500 mg | In stock | $ 169 | |
1 g | In stock | $ 250 | |
5 g | In stock | $ 800 |
Description | Camptothecin (NSC-100880, CPT, Campathecin, (S)-(+)-Camptothecin) is a specific inhibitor of DNA topoisomerase I (Topo I) with an IC50 of 0.68 μM. Camptothecin induces apoptosis in cancer cells through the microRNA- 125b-mediated mitochondrial signaling pathway to induce apoptosis. |
Targets&IC50 | Topoisomerase I:679 nM (IC50): Camptothecins:: |
In vitro | High TOP1 enzymatic activity MCF7 (Luminal subtype) and HCC1419 (HER2 subtype) show high sensitivity toward Camptothecin (0.1 μM to 5 μM; 72 hours) treatment, exhibiting the IC50 values of 0.089 μM and 0.067 μM, respectively.Camptothecin (0.5 μM; 6 and 24 hours) reduces desferrioxamine-activated VEGF expression.Camptothecin (0.5 μM; 8 to 24 hours) strongly prevents the desferrioxamine-dependent HIF-1a accumulation. |
In vivo | Camptothecin (2 mg/kg every other day) treats mice, has developed numerous pulmonary metastases.Treatment with both kinase inhibitor of nuclear factor-kappaB-1 (KINK-1) and Camptothecin led to a statistically significant reduction in the number of pulmonary metastases. |
CAS No. | 7689-03-4 |
Chemical Formula | C20H16N2O4 |
Molecular Weight | 348.35 |
Solubility | DMSO: 6.25 mg/mL (17.94 mM, Need ultrasonic) |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom